STOCK TITAN

Smith & Nephew Stock Price, News & Analysis

SNN NYSE

Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.

Smith & Nephew plc (NYSE: SNN, LSE: SN) is a global medical technology business whose news flow reflects activity across orthopaedics, sports medicine & ENT, and advanced wound management. Company announcements frequently highlight new product launches, clinical evidence, strategic partnerships and portfolio updates that are relevant to surgeons, healthcare providers and investors following SNN stock.

Recent news has showcased advanced wound management innovations, such as clinical data on the PICO◊ Single Use Negative Pressure Wound Therapy System demonstrating reductions in wound dehiscence, length of stay and costs versus an alternative device in orthopaedic and cardiovascular surgery, and studies on the ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing describing its mechanism in absorbing and dissipating shear forces linked to pressure injury risk.

In Sports Medicine, Smith+Nephew news items have covered the REGENETEN◊ Bioinductive Implant, including randomized controlled trial results and expanded indications to extra-articular ligament injuries, as well as updates on the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, including the establishment of a Category I CPT code recognising its clinical significance and adoption. Announcements also describe launches such as the Q-FIX™ KNOTLESS All-Suture Anchor and the CENTRIO Platelet-Rich-Plasma System for chronic exuding wounds.

Orthopaedics-related releases include the launch of the TRIGEN™ MAX Tibia Nailing System for tibial fractures and the expansion of CORIOGRAPH™ Pre-Op Planning and Modeling Services to total shoulder arthroplasty, alongside references to the AETOS◊ Shoulder System. Strategic and investor-focused news covers topics such as the RISE strategy, medium-term financial targets, and acquisitions like Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology.

Visitors to this SNN news page can review these updates in one place, tracking how Smith & Nephew presents clinical data, regulatory milestones, portfolio expansions, partnerships with organisations such as UFC and Wimbledon, and capital markets communications that shape the company’s profile in the global medical technology sector.

Rhea-AI Summary

Smith+Nephew (LSE:SN, NYSE:SNN) announces FDA clearance for CORIOGRAPH Pre-Op Planning and Modeling Services for total hip arthroplasty (THA). This innovative planning software, exclusive to CORI Surgical System users, enables both X-ray and CT scan planning for patient-specific outcomes.

The system leverages 15+ years of clinical expertise and over 350,000 image-based hip and knee surgery plans. Key features include advanced modeling capabilities with patient-specific spinopelvic classification, image-agnostic planning with 2D/3D images, and compatibility across Smith+Nephew's hip implant solutions.

The first procedures were completed at Orlando Health Jewett Orthopedic Institute, with surgeons reporting improved accuracy and optimization of component positioning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) has received FDA 510(k) clearance for its AETOS Stemless, a new stemless anatomic total shoulder implant. This addition expands the AETOS Shoulder System portfolio, which was introduced last year. The device features an inlay collar, cruciate fins, and porous titanium coating designed to encourage biological fixation and maximize stability.

The AETOS Stemless allows for streamlined convertibility from Stemless to Meta Stem, offering surgeons more flexibility in personalizing treatments. The system is cleared for use in the United States and approved in Canada, complementing Smith+Nephew's Sports Medicine shoulder repair and biologics solutions. Total shoulder arthroplasty is projected to reach 250,000 procedures annually in the US by 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary

Smith+Nephew's RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category. This award recognizes its intuitive pairing of NPWT in a patient-friendly design. The system, launched in 2024, is designed for treating chronic wounds, which affect an estimated 8.2 million people in the US with an annual financial burden of $33 billion.

The RENASYS EDGE NPWT System is lightweight, compact, and quiet, allowing patients to easily carry or wear it without drawing attention to their condition. This design consideration is crucial, as 68% of patients with chronic wounds often become self-conscious and isolated. Smith+Nephew's focus on patient-centric design is further evidenced by their PICO◊ 14 NPWT System, which also won a Red Dot Award for Design Concept in 2021 for its portable and discreet design.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
Rhea-AI Summary

Smith+Nephew (LSE:SN, NYSE:SNN) has signed a co-marketing agreement with JointVue for its OrthoSonic™ 3D Surgery Planning Technology, the only ultrasound device currently on the market to deliver 3D preoperative planning. This technology will be used with Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty, allowing surgeons to create personalized surgical plans.

The combination offers an ideal solution for Ambulatory Surgery Centers (ASCs) where OR space is JointVue's technology provides a radiation-free, automated planning tool that generates a 3D plan within minutes, guiding surgeons to tailor procedures uniquely to each patient. This partnership expands the imaging modalities available to Smith+Nephew customers for pre-op robotic planning, potentially improving patient satisfaction and operating room efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
partnership
-
Rhea-AI Summary

Smith+Nephew has launched the LEGION Hinged Knee (HK) System with OXINIUM Technology in the United States. This system, part of the LEGION Total Knee System, is designed to provide a natural range of motion and allows surgeons to transition intraoperatively from a constrained revision knee implant to a hinged assembly. The OXINIUM Technology offers several advantages over traditional materials, including:

  • Lower inflammatory response
  • Superior wear resistance
  • Reduced surface damage
  • Fewer signs of corrosion damage

These benefits help mitigate common risk factors associated with revision procedures. The LEGION revision with OXINIUM Technology has demonstrated the lowest risk of re-revision compared to the class average.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
-
Rhea-AI Summary

Smith+Nephew (LSE:SN, NYSE:SNN) has announced positive feedback from the first surgical cases using its new CATALYSTEM Primary Hip System. The system, designed for primary hip surgery, features a triple-taper stem design with uniform proximal loading and reduced distal stem geometry, making it ideal for anterior approach procedures. Key features include:

1. RI.HIP NAVIGATION for enhanced patient outcomes
2. Proprietary ACCUBROACH Technology for reproducible stem seating
3. User-friendly instruments suitable for direct anterior approach
4. Superior cutting and precise feel for rotational stability

Surgeons praised the system's precision, efficiency, and anatomical fit. The CATALYSTEM Primary Hip System represents a significant advancement in hip replacement technology, combining advanced technology with patient personalization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
Rhea-AI Summary

Cadence, a leading provider of contract manufacturing solutions for MedTech and Pharma markets, has appointed Bob White to its Board of Directors. White brings over 25 years of business leadership experience, with a focus on operational excellence, technological innovation, and strategic growth. He previously served as Executive Vice President and Group President at Medtronic, managing five global businesses across 70 countries. White's experience includes:

- Leading 25,000 employees and 13 manufacturing facilities
- Achieving consistent above-market growth
- Completing seven acquisitions, a joint venture, and a multi-billion-dollar divestiture

White currently serves as an Independent Director for Smith & Nephew (NYSE: SNN) and holds an MBA from Case Western Reserve University. His appointment is expected to contribute significantly to Cadence's strategic goals and market approach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
management
-
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) has launched TOTAL ANKLE Patient-Matched Guides for total ankle replacement (TAR) procedures. This innovative system, developed in partnership with 3D Systems, offers surgeons a predictable and efficient option for planning and performing TAR. Key benefits include:

1. Predictability in the OR with integrated fluoroscopic cues and all-in-one instrumentation
2. Accuracy to plan through fluoroscopic alignment cues and standard instrumentation
3. User-friendly design providing tactile feedback and precise patient fit

The guides are compatible with Smith+Nephew's CADENCE and SALTO TALARIS Total Ankle Systems. This launch strengthens the company's position in the growing TAR market, which is expected to see a CAGR of 6.98% through 2031.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
Rhea-AI Summary

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a three-year distribution agreement with Smith+Nephew for its negative pressure wound therapy (NPWT) system. InfuSystem will offer Smith+Nephew's advanced RENASYS◊ EDGE NPWT system, a lightweight and compact option for home-based care of chronic wounds.

The partnership leverages InfuSystem's Patient Services platform and network of over 800 in-network health insurance providers, covering 96% of the U.S. population. This collaboration aims to increase patient access to the RENASYS EDGE technology and create new revenue opportunities for both companies.

InfuSystem's CEO, Richard DiIorio, emphasized the company's ability to provide customized solutions and high-value services around partners' products, making them an attractive secondary distribution partner for Smith+Nephew's NPWT system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
Rhea-AI Summary

Smith+Nephew (LSE:SN, NYSE:SNN) has announced an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) to enhance solutions for Ambulatory Surgery Center (ASC) customers, physicians, and patients. The partnership integrates HOPCo's AI-powered myrecovery platform and Vitals platform with Smith+Nephew's CORI Surgical System.

This collaboration aims to provide comprehensive technology for all musculoskeletal procedures in ASCs, offering patient engagement tools, remote care management, and critical quality outcome metrics. The integration will enhance analytics for personalized surgical planning, intra-operative decision-making, and patient-reported outcomes tracking, potentially improving patient outcomes and reducing costs in value-based care settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
partnership AI

FAQ

What is the current stock price of Smith & Nephew (SNN)?

The current stock price of Smith & Nephew (SNN) is $32.74 as of April 22, 2026.

What is the market cap of Smith & Nephew (SNN)?

The market cap of Smith & Nephew (SNN) is approximately 14.0B.